Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Sorio

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Cells|December 22, 2019
TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer CellsMaura Sonego, Evelina Poletto, Eliana Pivetta, et al.
Investigational New Drugs|November 6, 2004
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancerFrancesco Caponigro, Pax Willemse, Roberto Sorio, et al.
Archives of Gynecology and Obstetrics|July 8, 2011
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?Gianmaria Miolo, Ettore Bidoli, Davide Lombardi, et al.
Tumori|April 13, 2012
Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experienceDiana Crivellari, Simon Spazzapan, Davide Lombardi, et al.
Gynecologic Oncology|March 2, 2022
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study databaseFrancesca Falcone, Mario Malzoni, Marco Carnelli, et al.
Cells|June 15, 2019
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) ApproachMarica Garziera, Rossana Roncato, Marcella Montico, et al.
Pharmacogenomics|September 8, 2020
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancerSara Gagno, Michele Bartoletti, Chiara Romualdi, et al.
Scientific Reports|August 4, 2017
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cellsMaura Sonego, Ilenia Pellizzari, Alessandra Dall'Acqua, et al.
Tumori|November 11, 2003
Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institutionMassimo Libra, Renato Talamini, Diana Crivellari, et al.
Clinical Nuclear Medicine|July 13, 2012
Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalitiesLidija Antunovic, Marino Cimitan, Eugenio Borsatti, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cells|December 22, 2019
TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer CellsMaura Sonego, Evelina Poletto, Eliana Pivetta, et al.
Investigational New Drugs|November 6, 2004
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancerFrancesco Caponigro, Pax Willemse, Roberto Sorio, et al.
Archives of Gynecology and Obstetrics|July 8, 2011
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?Gianmaria Miolo, Ettore Bidoli, Davide Lombardi, et al.
Tumori|April 13, 2012
Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experienceDiana Crivellari, Simon Spazzapan, Davide Lombardi, et al.
Gynecologic Oncology|March 2, 2022
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study databaseFrancesca Falcone, Mario Malzoni, Marco Carnelli, et al.
Cells|June 15, 2019
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) ApproachMarica Garziera, Rossana Roncato, Marcella Montico, et al.
Pharmacogenomics|September 8, 2020
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancerSara Gagno, Michele Bartoletti, Chiara Romualdi, et al.
Scientific Reports|August 4, 2017
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cellsMaura Sonego, Ilenia Pellizzari, Alessandra Dall'Acqua, et al.
Tumori|November 11, 2003
Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institutionMassimo Libra, Renato Talamini, Diana Crivellari, et al.
Clinical Nuclear Medicine|July 13, 2012
Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalitiesLidija Antunovic, Marino Cimitan, Eugenio Borsatti, et al.
Pageof 6